This company has been marked as potentially delisted and may not be actively trading. Presbia (LENS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LENS vs. NVCR, LMAT, UFPT, ATRC, ATEC, TNDM, AORT, FNA, PLSE, and IARTShould you be buying Presbia stock or one of its competitors? The main competitors of Presbia include NovoCure (NVCR), LeMaitre Vascular (LMAT), UFP Technologies (UFPT), AtriCure (ATRC), Alphatec (ATEC), Tandem Diabetes Care (TNDM), Artivion (AORT), Paragon 28 (FNA), Pulse Biosciences (PLSE), and Integra LifeSciences (IART). Presbia vs. Its Competitors NovoCure LeMaitre Vascular UFP Technologies AtriCure Alphatec Tandem Diabetes Care Artivion Paragon 28 Pulse Biosciences Integra LifeSciences Presbia (NASDAQ:LENS) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do analysts prefer LENS or NVCR? NovoCure has a consensus price target of $32.83, indicating a potential upside of 93.14%. Given NovoCure's stronger consensus rating and higher possible upside, analysts plainly believe NovoCure is more favorable than Presbia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Presbia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is LENS or NVCR more profitable? NovoCure has a net margin of -26.41% compared to Presbia's net margin of -36,604.35%. NovoCure's return on equity of -45.46% beat Presbia's return on equity.Company Net Margins Return on Equity Return on Assets Presbia-36,604.35% -414.02% -195.56% NovoCure -26.41%-45.46%-13.34% Does the media refer more to LENS or NVCR? In the previous week, NovoCure had 2 more articles in the media than Presbia. MarketBeat recorded 2 mentions for NovoCure and 0 mentions for Presbia. NovoCure's average media sentiment score of 1.38 beat Presbia's score of 0.00 indicating that NovoCure is being referred to more favorably in the news media. Company Overall Sentiment Presbia Neutral NovoCure Positive Which has higher valuation and earnings, LENS or NVCR? Presbia has higher earnings, but lower revenue than NovoCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPresbia$20K24,103.56-$8.41MN/AN/ANovoCure$605.22M3.13-$168.63M-$1.51-11.26 Do institutionals & insiders hold more shares of LENS or NVCR? 16.4% of Presbia shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 74.2% of Presbia shares are owned by company insiders. Comparatively, 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, LENS or NVCR? Presbia has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Does the MarketBeat Community believe in LENS or NVCR? NovoCure received 322 more outperform votes than Presbia when rated by MarketBeat users. However, 68.42% of users gave Presbia an outperform vote while only 62.98% of users gave NovoCure an outperform vote. CompanyUnderperformOutperformPresbiaOutperform Votes15668.42% Underperform Votes7231.58% NovoCureOutperform Votes47862.98% Underperform Votes28137.02% SummaryNovoCure beats Presbia on 11 of the 16 factors compared between the two stocks. Get Presbia News Delivered to You Automatically Sign up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENS vs. The Competition Export to ExcelMetricPresbiaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$482.07M$227.09M$5.41B$8.71BDividend YieldN/AN/A5.38%4.23%P/E RatioN/A5.1625.7519.52Price / Sales24,103.5666.66399.01108.92Price / CashN/A196.1225.4426.73Price / Book310.8710.508.015.73Net Income-$8.41M-$26.25M$3.15B$248.44M Presbia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENSPresbiaN/A$27.98-0.2%N/AN/A$482.07M$20K0.0024NVCRNovoCure4.3006 of 5 stars$17.43-2.7%$32.83+88.4%-12.9%$1.94B$621.71M-12.451,320Positive NewsLMATLeMaitre Vascular2.8553 of 5 stars$81.01-1.3%$97.83+20.8%+2.3%$1.83B$226.26M44.27490Positive NewsUFPTUFP Technologies0.5837 of 5 stars$235.81-0.7%$252.00+6.9%-11.2%$1.82B$547.56M33.642,020Positive NewsATRCAtriCure3.699 of 5 stars$32.60+0.9%$50.67+55.4%+39.1%$1.61B$480.08M-34.321,050Positive NewsATECAlphatec4.4828 of 5 stars$10.85-1.5%$17.89+64.9%+7.6%$1.59B$642.27M-8.48700TNDMTandem Diabetes Care4.1271 of 5 stars$20.07+0.1%$33.43+66.6%-52.8%$1.34B$982.95M-10.402,600Positive NewsAnalyst DowngradeAORTArtivion2.5844 of 5 stars$29.77+3.6%$32.00+7.5%+32.2%$1.27B$390.08M-1,488.501,300Positive NewsFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+128.3%$1.10B$256.18M-17.71343,000High Trading VolumePLSEPulse Biosciences1.4608 of 5 stars$15.04-1.9%N/A+44.2%$1.01B$700K0.00140Positive NewsIARTIntegra LifeSciences4.4004 of 5 stars$12.15-1.9%$18.63+53.3%-60.6%$944.20M$1.62B-134.993,720Gap Up Related Companies and Tools Related Companies NVCR Competitors LMAT Competitors UFPT Competitors ATRC Competitors ATEC Competitors TNDM Competitors AORT Competitors FNA Competitors PLSE Competitors IART Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENS) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Presbia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LENS Stock Free LENS Stock Alerts